Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma

• Published in: Blood Vol. 121; no. 6; pp. 884 - 892
• Main Authors: Bergsagel, P. Leif, Mateos, María-Victoria, Gutierrez, Norma C., Rajkumar, S. Vincent, San Miguel, Jesús F.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 07.02.2013; American Society of Hematology
• Subjects: Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Boronic Acids - administration & dosage; Boronic Acids - therapeutic use; Bortezomib; Chromosome Aberrations; Clinical Trials and Observations; Dexamethasone - administration & dosage; Dexamethasone - therapeutic use; Humans; Lenalidomide; Lymphoid Neoplasia; Multiple Myeloma - drug therapy; Multiple Myeloma - genetics; Multiple Myeloma - pathology; Prognosis; Pyrazines - administration & dosage; Pyrazines - therapeutic use; Randomized Controlled Trials as Topic; Risk Factors; Survival Analysis; Thalidomide - administration & dosage; Thalidomide - analogs & derivatives; Thalidomide - therapeutic use; Treatment Outcome
• ISSN: 0006-4971; 1528-0020
• DOI: 10.1182/blood-2012-05-432203

Multiple myeloma (MM) is a heterogeneous disease with certain genetic features [eg, t(4;14), del17p] associated with worse outcome. The introduction of thalidomide, lenalidomide, and bortezomib has dramatically improved the outlook for patients with MM, but their relative benefit (or harm) for different genetic patient subgroups remains unclear. Unfortunately, the small number of patients in each subgroup frequently limits the analysis of high-risk patients enrolled in clinical trials. Strategies that result in survival of high-risk genetic subgroups approximating that of patients lacking high-risk features are said to overcome the poor prognostic impact of these high-risk features. This outcome has been difficult to achieve, and studies in this regard have so far been limited by inadequate sample size. In contrast, strategies that compare the survival of high-risk genetic subgroups randomized to different treatment arms can identify approaches that improve survival. This type of analysis is clinically useful, even if the absolute gains do not improve outcomes to levels seen in patients without high-risk cytogenetics. Reviewing available data in high-risk MM from this perspective, it appears that bortezomib has frequently been associated with improved survival, whereas thalidomide maintenance has sometimes been associated with a shorter survival.